The Combination of Dupilumab with Other Monoclonal Antibodies.
Paolo GisondiM MaurelliA CostanzoM EspositoG GirolomoniPublished in: Dermatology and therapy (2022)
Because the evidence is modest, the question remains open as to whether dupilumab can be safely combined with other monoclonal antibodies. Dupilumab does not exert immunosuppressive effects and does not impair the activity of cytochrome P450 isozymes.
Keyphrases